4.6 Article

A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs

期刊

JOURNAL OF IMMUNOLOGY
卷 207, 期 1, 页码 344-351

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.2100155

关键词

-

资金

  1. National Institutes of Health [R37AI059714, R01AI132317, UM1 44462]

向作者/读者索取更多资源

This study introduces a rapid and accurate assay for detecting receptor binding domain nAbs, utilizing a proximity-based luciferase assay. The method was validated and shown to be particularly useful in HIV patients, offering a cost-effective and real-time alternative for evaluating the potency of SARS-CoV-2 nAbs induced by infection or vaccines.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike pseudotyped virus (PSV) assays are widely used to measure neutralization titers of sera and of isolated neutralizing Abs (nAbs). PSV neutralization assays are safer than live virus neutralization assays and do not require access to biosafety level 3 laboratories. However, many PSV assays are nevertheless somewhat challenging and require at least 2 d to carry out. In this study, we report a rapid (<30 min), sensitive, cell-free, off-the-shelf, and accurate assay for receptor binding domain nAb detection. Our proximity-based luciferase assay takes advantage of the fact that the most potent SARS-CoV-2 nAbs function by blocking the binding between SARS-CoV-2 and angiotensin-converting enzyme 2. The method was validated using isolated nAbs and sera from spike-immunized animals and patients with coronavirus disease 2019. The method was particularly useful in patients with HIV taking antiretroviral therapies that interfere with the conventional PSV assay. The method provides a cost-effective and point-of-care alternative to evaluate the potency and breadth of the predominant SARS-CoV-2 nAbs elicited by infection or vaccines.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据